GTXI GTx, Inc. featured news, full reports, and detailed charts
GTx, Inc. (GTXI) Wrap Up:
GTx, Inc., a Delaware corporation incorporated on September 24, 1997, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. We are developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of multiple serious side effects of androgen deprivation therapy, or ADT, for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia, or high grade PIN. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f11%2f0000950144-08-001812.html#FIS_BUSINESS"www.gtxinc.com
147 Employees
Founded in 1997
GTX Inc. (GTXI:NASDAQ)
LAST $3.51 USD
CHANGE TODAY +0.24 7.34%
VOLUME 737.9K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of GTX Inc. (GTXI)
|
OPEN
$3.32
|
PREVIOUS CLOSE
$3.27
|
|
|
DAY HIGH
$3.53
|
DAY LOW
$3.27
|
|
|
52 WEEK HIGH
12/18/08 - $18.75
|
52 WEEK LOW
11/19/09 - $3.22
|
|
|
MARKET CAP
127.8M
|
AVERAGE VOLUME 3 mo
747.9K
|
|
|
DILUTED EPS TTM
$-1.35
|
SHARES OUTSTANDING
36.4M
|
|
|
GTXI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
GTXI Top Compensated Officers
Dr. Mitchell S. Steiner
Co-Founder, Vice Chairman and Chief Executive...
Age: 48
Total Annual Compensation: $500.0K
Mr. Marc S. Hanover MBA
Co-Founder, President, Chief Operating Office...
Age: 46
Total Annual Compensation: $435.0K
Mr. Mark E. Mosteller CPA
Chief Financial Officer, Principal Accounting...
Age: 46
Total Annual Compensation: $283.9K
Dr. Ronald A. Morton Jr., M.D., FACS
Chief Medical Officer and Vice President
Age: 50
Total Annual Compensation: $458.5K
Mr. Henry P. Doggrell
Vice President, Secretary and General Counsel
Age: 60
Total Annual Compensation: $265.7K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for GTX Inc. (GTXI)
GTX Inc. to Report Q3, 2009 Results on November 09, 2009
11/4/2009
GTX Inc. announced that they will report Q3, 2009 results before the start of trading on November 09, 2009.
GTX Inc., Q3 2009 Earnings Call, Nov--09-2009
11/4/2009
GTX Inc., Q3 2009 Earnings Call, Nov-09-2009
GTX Inc. Receives Complete Response Letter from United States Food and Drug Administration
11/2/2009
GTX Inc. announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration regarding its New Drug Application for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). The FDA identified two deficiencies in the Complete Response Letter and recommended that the following information be provided to the FDA to address these clinical deficiencies: (i) results of a second adequate and well controlled Phase III trial demonstrating the safety and efficacy of toremifene citrate 80mg to reduce fractures in men with prostate cancer on ADT and (ii) results from an adequate and well-controlled clinical trial demonstrating that toremifene treatment to reduce fractures in men with prostate cancer on ADT does not have a detrimental effect on either time-to-disease progression or overall survival. GTx is requesting a meeting with the FDA to determine the appropriate next steps regarding the NDA.
GTXI Competitors
| Company | Last | Change |
| AstraZeneca | 2,695 GBX | -11.50 |
| Biodel Inc | $4.15 USD | +0.40 |
| Keryx Biopharmaceuticals Inc | $2.30 USD | -0.05 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | GTXI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 9.1x |
|
| Price/Book | 5,334.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 5.1x |
|
|
GTXI |
||
|
GTXI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About GTx, Inc.
More news for GTXI
GTx, Inc. Reports Third Quarter 2009 Corporate Results
 GTx, Inc. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited)    Three Months Ended September 30,   Nine Months Ended September 30, 2009   2008 2009   2008   Revenues: ...Click here to read the whole Article (external link)
GTx, Inc. Earnings Call scheduled for 9:00 am ET today
Call DetailsGTx, Inc. Earnings Conference Call (Q3 2009)Mon, Nov 9, 2009, 9:00 am EasternAbout GTx, Inc. (NasdaqGM:GTXI)Other Calls GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial. It also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx’s preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc....Click here to read the whole Article (external link)
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
Show all filings for GTX INC /DE/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for GTX INC /DE/ 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not in...Click here to read the whole Article (external link)
Q3 2009 GTx, Inc. Earnings Release - Before Market Open
Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...Click here to read the whole Article (external link)
GTx loss widens in third quarter
GTx Inc. reported $3.6 million in third quarter revenue, a slight drop from the $3.8 million the company reported for the second quarter of 2009. GTx reported revenues of $3 million for the third quarter of 2008. Memphis-based GTx’s revenues included net sales of FARESTON 60 mg, a metastatic breast cancer drug for postmenopausal women and collaboration revenue with Ipsen Developments Limited and Merck & Co. Inc. Collaboration revenue was $2.9 million for the third quarter of 2009, compared to $2.7 million for the third quarter 2008. GTx (Nasdaq: GTXI) also reported a net loss of $12.8 million or 35 cents per share for the quarter and $35.4 million or 97 cents per share for the year, compared to a net loss of $11.9 million or 33 cents and $37.9 million or $1.05 for the same periods in 2008. GTx is also determining a new course of action after the FDA’s response to its thought-to-be completed trials for toremifene 80 mg. The FDA is requiring the company to conduct two more trials. GTx has requested a meeting with the FDA that should take place in the next 30 days. Toremifene is designed to reduce fractures in men with prostate cancer on androgen deprivation therapy. “Following the FDA's response on the NDA, we are committed to working with the agency to understand the next steps required to bring this drug to patients,” Mitchell Steiner, CEO of GTx, said in a statement. “We have this important product as well as a valuable pipeline of first-in-class drugs addressing large unmet medical needs which are advancing in clinical development." Shares of GTx stock fell 3.6 percent to close Monday at $3.73 per share. The stock has lost more than half its value in the past week. GTx is a biopharmaceutical company b...Click here to read the whole Article (external link)
GTx 3Q loss widens on higher costs
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Earnings roundup: GTx, Caliper Life Sciences
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
GTX INC /DE/ Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue3,600 3,822 3,631 2,998 Cost of Revenue344 431 348 167 Gross Profit3,256 3,391 3,283 2,831 Operating ExpensesResearch Development8,123 7,746 8,312 10,646 Selling General and Administrative7,982 6,940 6,542 6,324 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(12,849)(11,295)(11,571)(14,139)Income from Continuing OperationsTotal Other Income/Expenses Net29 35 76 271 Earnings Before Interest And Taxes(12,820)(11,260)(11,495)(13,868)Interest Expense - - - - Income Before Tax(12,820)(11,260)(11,495)(13,868)Income Tax Expense - - (194) - Minority Interest - - - - Net Income From Continuing Ops(12,820)(11,260)(11,301)(13,868)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - - - ...Click here to read the whole Article (external link)
GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Would you like to leave a comment about GTx, Inc. GTXI
Find out what social network information about GTx, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides GTx, Inc. there is more great information available at Realpennies.com